Analysts from Cantor Fitzgerald have initiated a positive outlook on InflaRx (IFRX, Financial), assigning it an Overweight rating accompanied by a price target of $10. A significant milestone expected in May could shift market perceptions about the company. This involves interim data from a Phase 3 trial for their leading treatment candidate, vilobelimab, aimed at addressing pyoderma gangrenosum. According to analysts, this upcoming data release represents a substantial opportunity for InflaRx, with the potential to significantly influence investor sentiment. The anticipated interim results carry a notably favorable risk-to-reward proposition, suggesting a promising outlook for the company’s stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for InflaRx NV (IFRX, Financial) is $9.24 with a high estimate of $13.05 and a low estimate of $5.02. The average target implies an upside of 657.05% from the current price of $1.22. More detailed estimate data can be found on the InflaRx NV (IFRX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, InflaRx NV's (IFRX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
